Romilkimab delivers in diffuse cutaneous systemic sclerosis
Romilkimab, a novel bispecific immunoglobulin-G4 antibody that binds and neutralizes interleukin (IL)-4/IL-13, shows promise in the treatment of diffuse cutaneous systemic sclerosis, producing significant reduction in skin fibrosis, according to the results of a phase II trial.